ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,223.98
-0.44%
Dow Jones
42,732.13
0.80%
Gold vs US Dollar
2,640.60
0.00%
Brent Oil
76.495
0.00%
Bitcoin
97,701.56
-0.41%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Vertex Pharmaceuticals Inc (VRTX) Share Price

VRTX Vertex Pharmaceuticals Inc

407.11
1.35 (0.33%)
04 Jan 2025 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Vertex Pharmaceuticals Inc NASDAQ:VRTX NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   1.35 0.33 407.11 400.00 410.00 411.65 406.40 407.52 1,073,948 01:00:00   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations 9.92B 3.57B 13.8641 29.36 104.5B
 Type  Size  Price  Time  Units 
 9 1 406.68 00:58:38 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore VRTX News
23/12/202421:05BWVertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
20/12/202420:51EDGAR2Form 8-K - Current report
20/12/202420:46BWVertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
20/12/202420:35BWVertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
19/12/202411:00BWVertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
08/12/202417:52BWVertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
19/11/202421:08EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
Period
Draw mode
Data Downloads for VRTX

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Vertex Pharmaceuticals Inc Articles

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads